Labcorp Announces Board & Executive Compensation Changes

Ticker: LH · Form: 8-K · Filed: 2025-12-15T00:00:00.000Z

Sentiment: neutral

Topics: board-changes, executive-compensation, corporate-governance

TL;DR

Labcorp's board is changing, exec pay is being adjusted.

AI Summary

Labcorp Holdings Inc. announced on December 9, 2025, changes in its board and executive compensation. Specifically, the company reported the departure of a director, the election of a new director, and adjustments to the compensatory arrangements for certain officers. The filing details these changes as required by SEC regulations.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing board and compensation changes, with no immediate financial or operational risks indicated.

Key Numbers

Key Players & Entities

FAQ

Who is the departing director and who is the newly elected director?

The filing indicates the departure of a director and the election of a new director, but their specific names are not provided in this excerpt.

What specific changes were made to the compensatory arrangements of certain officers?

The filing states that there were changes to the compensatory arrangements of certain officers, but the details of these arrangements are not specified in this excerpt.

What is the exact date of the earliest event reported in this 8-K filing?

The earliest event reported is dated December 9, 2025.

What is Labcorp's principal executive office address?

Labcorp's principal executive offices are located at 358 South Main Street, Burlington, North Carolina 27215.

Under which section of the Securities Exchange Act of 1934 is this Current Report filed?

This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0000920148-25-000123.txt : 20251215 0000920148-25-000123.hdr.sgml : 20251215 20251215160347 ACCESSION NUMBER: 0000920148-25-000123 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251209 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20251215 DATE AS OF CHANGE: 20251215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LABCORP HOLDINGS INC. CENTRAL INDEX KEY: 0000920148 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 992588107 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11353 FILM NUMBER: 251571550 BUSINESS ADDRESS: STREET 1: 358 S MAIN ST CITY: BURLINGTON STATE: NC ZIP: 27215 BUSINESS PHONE: 3362291127 MAIL ADDRESS: STREET 1: 358 S MAIN ST CITY: BURLINGTON STATE: NC ZIP: 27215 FORMER COMPANY: FORMER CONFORMED NAME: LABORATORY CORP OF AMERICA HOLDINGS DATE OF NAME CHANGE: 19950504 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL HEALTH LABORATORIES HOLDINGS INC DATE OF NAME CHANGE: 19940314 8-K 1 lh-20251209.htm 8-K lh-20251209 0000920148 false 0000920148 2025-12-09 2025-12-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 9, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 358 South Main Street   Burlington , North Carolina 27215 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number including area code) 336 - 229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol Name of exchange on which registered Common Stock, $0.10 par value LH New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).              Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 9, 2025, Mark Schroeder, the Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer of Labcorp Holdings Inc. (the “Company”), notified the Company of his intention to retire, effective on April 1, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LABCORP HOLDINGS INC. Registrant Date: December 15, 2025 By: /s

View on Read The Filing